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A R T I C L E I N F O A B S T R A C T
Objectives:Many trials have shown that intensive management is effective in patients with early active rheu-
matoid arthritis (RA). But its benefits are unproven for the large number of RA patients seen in routine care
who have established, moderately active RA and are already taking conventional synthetic disease modifying
anti-rheumatic drugs (csDMARDs). The TITRATE trial studied whether these patients also benefit from inten-
sive management and, in particular, achieve more remissions.
Methods: A 12-month multicentre individually randomised trial compared standard care with monthly intensive
management appointments which was delivered by specially trained healthcare professionals and incorporated
monthly clinical assessments, medication titration and psychosocial support. The primary outcome was 12-
month remission assessed using the Disease Activity Score for 28 joints using ESR (DAS28-ESR). Secondary out-
comes included fatigue, disability, harms and healthcare costs. Intention-to-treat multivariable logistic- and linear
regression analyses compared treatment armswith multiple imputation used for missing data.
Results: 459 patients were screened and 335 were randomised (168 intensive management; 167 standard care);
303 (90%) patients provided 12-month outcomes. Intensive management increased DAS28-ESR 12-month remis-
sions compared to standard care (32% vs 18%, p = 0.004). Intensive management also significantly increased
remissions using a range of alternative remission criteria and increased patients with DAS28-ESR low disease
activity scores. (48% vs 32%, p = 0.005). In addition it substantially reduced fatigue (mean difference -18; 95% CI:
-24, -11, p<0.001). There was no evidence that serious adverse events (intensive management =15 vs standard
care =11) or other adverse events (114 vs 151) significantly increase with intensive management.
Interpretation: The trial shows that intensive management incorporating psychosocial support delivered by
specially trained healthcare professions is effective in moderately active established RA. More patients
achieve remissions, there were greater improvements in fatigue, and there were no more harms.
© 2020 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/)
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Introduction
Despite the increasing availability of biological and other innova-
tive therapies, rheumatoid arthritis (RA) remains a major health
problem [1-3]. Current treatment recommendations in clinical guide-
lines advocate intensive management using treat-to-target strategies
[4, 5]. There is strong evidence these are effective in early RA patients
with high disease activity [6-9]. However, a large number of patients
followed in specialist units who are receiving conventional synthetic
disease modifying anti-rheumatic drugs (csDMARDs) continue to
have moderately active established RA [10, 11]. Despite the known
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poor long-term outcomes of these patients, there is uncertainty
whether they too will benefit from intensive management.
The TITRATE trial took place in routine care settings across multiple
centres with management delivered by specialist nurses and other
health care professionals who had completed a targeted two day train-
ing programme. It evaluated the effectiveness of intensive management
in moderately active established RA. Based on monthly clinical assess-
ments drug therapy was optimised and patients also received psycho-
social support delivered by trained nurses and other practitioners using
motivational interviewing techniques [12]. One previous trial in such
patients, the British Rheumatoid Outcome Study Group (BROSG), under-
taken in the pre-biological era [13]; found intensive management using
csDMARDs achieved only modest increases in remission and the differ-
ences were not significant. North American experience with similar
patients has been variable. Harrold et al. found no benefit from treat to
target approaches [14]. In contrast studies by Solomon et al. found bene-
fit after training clinicians involved in general principles of management
[15-17]. Uncertainty about the benefits of intensive management in
moderately active established RA remains an important challenge when
generalising treat-to-target approaches [18].
The TITRATE trial bridges this evidence gap by testing the hypoth-
esis that 12-months of intensive management in patients with estab-
lished moderately-active RA given in conjunction with psychosocial
support provides more remissions than standard care.
Patients and methods
Design
An open-label, 12-month, pragmatic, randomised, multicentre,
two-arm, parallel group superiority trial.
Participants
Patients were recruited from 39 English rheumatology centres.
Included patients comprised: males and females over 18 years; who
met 2010 RA classification criteria [19]; had received 6 months
csDMARDs; were currently receiving at least one csDMARD; had
moderate/ intermediate disease activity (DAS28-ESR 3.25.1 with
three or more swollen and/or tender joints out of 66/68 and at least
one swollen joint); were able and willing to follow intensive manage-
ment. Patients were excluded who had comorbidities making treat-
ment intensification inadvisable (e.g. heart failure); had failed 5
csDMARDs; received biologics; had irreversible disability from exten-
sive joint damage; were pregnant, breast-feeding or women planning
to conceive; had recently participated in another clinical trial; and
were currently on early RA management pathway.
Interventions
Drug treatment complied with guidance from the National Insti-
tute for Health and Clinical Excellent (NICE) and the national special-
ist society (British Society for Rheumatology).
Standard Care: clinicians followed local pathways for managing
moderate disease activity patients reflecting national guidance [20,
21] without specific treatment and follow-up plans.
The approach for managing RA in England when the trial was
undertaken involved optimising csDMARD monotherapy, consider-
ing combination therapy with csDMARDs, and giving biologics if
patients had active disease despite failing to respond to two
csDMARDs.
Intensive Management: this was delivered by nurses and allied
healthcare professionals who had completed a 2-day training to fol-
low a pre-defined treatment support programme [22]. Monthly for
12 months they: (a) assessed disease activity; (b) reviewed drug
treatment; (c) modified drug treatment using a decision tool
reflecting “shared treatment plans” formulated with patients during
their first visit; and (d) provided supportive psychosocial care.
Intensive Management spanned four strands: (i) providing informa-
tion about RA with a handbook outlining treatments, side effects and
ways to cope with RA; (ii) optimising drug treatment with csDMARDs
and biologics using a treatment algorithm; (iii) giving intra-muscular
glucocorticoids if arthritis not fully controlled; and (iv) providing “treat-
ment support” focussing on pain and fatigue management; physical
activity; medication adherence, sleep and mood. Treatment support
used techniques taken from motivational interviewing (MI) [23, 24].
Intensive management consultations were audio recorded by rheuma-
tology practitioners with patients’ consent. A 10% sample of all recorded
consultations were assessed against a fidelity checklist developed for
TITRATE [12] to monitor the delivery of MI techniques [25].
Primary Outcome: DAS28-ESR remission (DAS28-ESR <2.6) at 12
months [26].
Secondary Outcomes: alternative measures of remission (DAS28-
CRP <2.6, SDAI3.3, CDAI 2.8 and ACR/EULAR Boolean remission)
[26, 27]) and low disease activity (DAS28-ESR 3.2) at 12 months;
tender (28/68) and swollen joint counts (28/66); erythrocyte sedi-
mentation rate (ESR); C-reactive protein (CRP); patient global and
assessor global assessments on 100 mm visual analogue scales (VAS);
pain and fatigue on 100 mm VAS; health assessment questionnaire
(HAQ) [28]; EuroQoL 5 Dimensional score (EQ5D-5 L) [29]; plain-film
X-rays of hands and feet scored using modified Larsen’s scores [30];
NHS and personal social service costs measured by modified Client
Service Receipt Inventory (CSRI) questionnaires [31].
Assessments
An anonymised electronic data capture system collected clinical
data. Demographic measures were recorded at baseline. Clinical out-
comes were assessed 6- monthly; X-rays were taken and assessed
annually.
Sample size
The most relevant UK treat-to-target trial in active early RA had
found 16% of standard care patients achieved end-point DAS remis-
sions [32]. We assumed 16% of standard care patients in TITRATE
would similarly achieve endpoint DAS28-ESR remission. We pro-
posed rejecting the null hypothesis (intermediate disease activity RA
patients receiving csDMARDs have no more remission after 12-
months intensive management) if remission rate increased by 15%.
Showing this difference with 5% significance level and 90% power
indicated the need to randomise 358 patients. Recruitment ended
after three years for organisational reasons with 335 patients rando-
mised (94% planned sample size) [12].
Randomisation
Potentially eligible patients were screened and reasons for non-
entry recorded. Consenting patients were individually randomised
using block randomisation with randomly varying block sizes. Strati-
fying by site ensured pre-randomisation allocation concealment.
Patients were randomised to intensive management or standard care
in a 1:1 ratio. Trial staff were unaware of the allocation sequence.
Blinding
TITRATE was un-blinded; patient involvement in intensive man-
agement made blinding impossible. Independent assessors unin-
volved in managing trial patients undertook follow up clinical
assessments. Pain, fatigue, disability and quality of life were self-
assessed by patients. X-ray reading was performed blinded to treat-
ment.
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Statistical methods
Randomised patients who received treatment were assessed on
an intention-to-treat (ITT) basis following CONSORT guidelines [33].
All participants had complete observations at baseline. Missing
observations during follow-up (Supplementary Table 1) were multi-
ply imputed regardless of the reason(s) they were missing. Predictive
mean matching with five nearest neighbours, assuming unobserved
measurements were missing at random was used to impute primary
and secondary outcomes. Sensitivity analysis assessed the robustness
of the missing at random assumption using pattern-mixture model
approach (Supplementary Table 2); it showed qualitatively similar
results; consequently, only the primary multiple imputation analyses
are reported. A complete case analysis was also undertaken.
Logistic regression analysis was used to evaluate the effect of Inten-
sive Management treatment on the primary outcome (12-month remis-
sion) and other binary outcomes. “Univariable” analyses of treatment
were adjusted for NHS region (design variable). “Multivariable” analyses
further adjusted for gender, ethnicity, age and disease duration. Linear
regression evaluated change from baseline to 12-months for the contin-
uous outcomes. Linear mixed models estimated the effect of treatment
over follow-up time; working correlation matrices were unstructured as
measurements were taken at three time points (i.e. baseline, 6 and 12
months). Interactions between time and treatment group were assessed
in these models and were found not to be significant at 5% level and
thus the main effect of treatment is reported in the various linear mixed
effects analyses after dropping the time by treatment interaction. Serious
and other adverse events were evaluated using comparisons of two
independent proportions. Analyses were undertaken using Stata 16 [34].
Economic analyses
NHS and personal social service costs measured from patient
resource use questionnaires and NHS hospital records; and adverse
events. Total costs and quality-adjusted life years were measured
using the EuroQol and combined to assess the health economic
effects of intensive management compared with standard care, which
was represented by an incremental cost-effectiveness ratio, see (Sup-
plementary Table 3).
Ethics approval
Ethical approval for this trial was obtained from the London 
West London & GTAC
National Research Ethics Service (NRES) Committee (13/LO/1308).
All participants provide written informed consent before participat-
ing in the trial or extension study.
Results
Patients and treatments
Recruitment: Between August 2014 and July 2017, 1405 patients
were invited to participate: 459 patients were screened; 335 patients
were randomised and treated (Fig. 1). 303/335 (90%) randomised
patients provided 12-month primary outcomes, including 3 patients
who withdrew but agreed to medical reviews (Fig. 1).
Baseline Data and Numbers Analysed: demographic and disease
assessments were similar in both groups (Table 1). The intention to
treat analysis included all 335 randomised patients (168 intensive
management/167 standard care); the complete case analysis assessed
258 patients (134 intensive management/124 standard care).
Baseline Treatments: all patients took at least one csDMARD; 15/
168 (9%) of intensive management patients and 14/168 (8%) of stan-
dard care patients took two. Methotrexate, the main csDMARD, was
taken by 81 intensive management and 86 standard care patients
and as part of csDMARD combinations in another 14 and 11 patients
respectively (Table 1).
Standard Care arm: 128 patients started another csDMARD, 35 a
second and 2 a third. csDMARD doses were increased in 32 patients
and decreased in 9. Biologics were started in 24 patients; 2 had a sec-
ond biological. biological doses were not increased in any patient and
were reduced in one during the study period. Depot steroid injections
were given to 50 patients: 28 received one injection; 19 received 24
injections and 3 had 5 or more injections (Table 2).
Intensive Management arm: 161/168 patients randomised to inten-
sive management attended 1 session, with 7 missing all sessions: 3
changed from intensive management to standard care after their first
visit; 4 withdrew from the study and were lost to follow up. 139/161
(86%) patients attended at least 8 of the planned sessions (mean 11,
SD 1.34) and 22/161 (14%) patients attended fewer than 8 visits
(mean 4, SD 1.94).
One hundred and forty patients started another csDMARD, 64 a
second and 3 a third. csDMARD doses were increased in 69 patients
and decreased in 15. Biologics were started in 46 patients: 7 had a
second biological and 2 had a third biological. biological doses were
increased in 2 patients and reduced in two during the study period.
Depot steroid injections were given to 72 patients: 22 received one
injection; 33 received 24 injections and 17  5 injections (Table 2).
A total of 126 sessions were assessed for fidelity to the MI techni-
ques. The data represented that of 42 patients across 19 research sites
and 25 trained rheumatology practitioners. Fidelity assessments
demonstrated 4 (3%) had poor fidelity to the taught techniques, 52
(41%) low fidelity, 58 (46%) moderate fidelity, and 12 (10%) high fidel-
ity [25]. However, some approaches were undertaken with moderate
or high fidelity, such as affirming the patient's strengths and abilities
were observed at moderate or high-fidelity levels.
Primary outcome
Intensive management increased 12-month DAS28-ESR remis-
sions (Table 3) compared to standard care [32% (95% CI: 25%, 40%) vs
18% (12%, 24%)]. The differences were significant in both unadjusted
and adjusted logistic regression analyses (P<0.01).
Other remissions and low disease activity
There were greater proportions of 12-month remissions in
DAS28-CRP, SDAI, CDAI and ACR/EULAR Boolean with intensive man-
agement (21%, 17%, 18% and 13%) than standard care (10%, 10%, 10%
and 6%) (Table 3).
Low disease activity states at 12 months were achieved by 48%
(39%, 56%) on intensive management and in 32% (25%, 40%) of stan-
dard care patients. The difference was statistically significant [unad-
justed odds ratio 1.94 (1.22, 3.10) P = 0.005], [adjusted odds ratio
2.04 (1.25, 3.31) P = 0.004].
Mean changes in the DAS28-ESR scores at 12 months from baseline
were lower 0.57 (95% CI: 0.88, 0.26; P=<0.001) in unadjusted;
0.51 (0.81, 0.21; P = 0.001) in adjusted regression analyses with
intensive treatment (Table 4). There were significant differences in
DAS28-CRP, SDAI and CDAI 12-months change scores, tender and swol-
len joint counts, and assessor and patient global 12-months change
scores between treatment arms. Howevermean ESR and C-reactive pro-
tein levels were unchanged during the trial without significant differ-
ence between groups at 12 months. There was only a small
improvement in disability as assessed by HAQ and quality of life
assessed bymean EQ5D; the difference between groups were not signif-
icant (Table 4).
Mean pain and fatigue scores were significantly lower with inten-
sive management in unadjusted and adjusted linear regression analy-
ses (Table 4). Clinically meaningful improvements in fatigue (10 units
or more) were achieved by 58% (95% CI: 51%, 66%) of patients
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receiving intensive management and 35% (95% CI: 28%, 42%) of
patients receiving standard care; logistic regression showed this dif-
ference was significant [adjusted odds ratio 2.81 (1.76, 4.48)
P<0.001]. Larsen X-ray scores increased from mean 11 to 13 with
intensive management and 9 to 10 with standard care; with no sig-
nificant differences between groups (Table 4).
Longitudinal clinical outcomes
Longitudinal analyses (over the three time points) assessed the
overall impact of treatment over time using mixed effects models
(Table 4). Unadjusted and adjusted analyses showed significant dif-
ferences between treatment groups for DAS28-ESR, swollen joint
counts for 66 joints, patient global assessments, fatigue and pain. The
treatment effects on fatigue between groups were particularly large;
15.7 (95% CI: 21.3, 10.1) in unadjusted and 13.1 (18.1, 8.1)
in adjusted analyses.
Complete case analyses
The effect of intensive management on remission and clinical out-
comes was maintained in the complete case analyses (data not
Fig. 1. CONSORT diagram for TITRATE Trial.
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shown). Additional regression analyses showed no evidence that the
use of steroids or biologics had an identifiable impact on 12-month
remission rates or mean DAS28-ESR, pain or fatigue
An additional exploratory analysis showed that patients who had
11 or 12 intensive management visits achieved the best outcomes in
terms of remissions and falls in 12-month DAS28-ESR, pain and
fatigue scores (Online Supplementary Figure).
Adverse events
There were 26 serious adverse events involving 24 patients: 15
with intensive management and 11 with standard care (Table 4);
there was no significant difference in the proportion of serious
adverse events between treatment groups (Chi-squared=0.64; DF=1;
P = 0.42). Three patients died: two on intensive management and one
on standard care; no death was considered treatment related. Other
serious adverse events spanned several systems; there was no indica-
tion any were treatment related (Table 5).
Overall, 132 patients (60 intensive management; 72 standard
care) had 265 adverse events (114 intensive management; 151 stan-
dard care) (Table 5). There was no evidence intensive management
increased adverse event risks; in fact, a smaller proportion of patients
with adverse events and a lower frequency of adverse events were
reported in the intensive management arm.
Cost-Effectiveness
Economic analysis showed the base case incremental cost-effec-
tiveness ratio was £43,972 (€51,474) from medical and personal
social service cost perspectives; the probability of meeting the
English willing to pay threshold (£30,000/€35,000) was 17%. The
incremental cost-effectiveness ratio fell to £29,363 (€24,384) after
including patients’ personal costs and lost working time; this corre-
sponded to 50% probability intensive management is cost-effective at
English willing to pay thresholds, see (Supplementary Table 4).
Discussion
The TITRATE trial showed that intensive management using
treat-to-target principles in patients with established moderate RA
gave substantially more remissions than standard care and more
patients achieved a low disease activity state. Intensive manage-
ment improved joint counts, global assessments of disease activity,
fatigue and pain compared with standard care, though neither ESR
nor C-reactive protein level were seen to fall with intensive man-
agement. There was no evidence intensive management led to
more harms. There were numerically more serious adverse events
with intensive management than standard care but fewer other
adverse events with no significant differences between groups.
Although we cannot be certain that in a large study the difference
in serious adverse events may be significant, we think this is
unlikely because previous systematic reviews of combination
DMARD therapies[35] and treat to target trials [8] showed no
increases in adverse events in many of these trials.
Table 1
Baseline Characteristics, Assessments And Treatments.
Assessments Intensive
Management
Standard Care
n = 168 n = 167
Demographic Age (Years) 56.4 (12.2) 56.8 (12.0)
Disease Duration (Years) 6.6 (7.0) 5.2 (5.5)
Female (%) 140 (83%) 130 (78%)
Clinical
Assessments
DAS28-ESR 4.4 (0.5) 4.3 (0.5)
DAS28-CRP 4.5 (0.6) 4.5 (0.6)
CDAI 19.7 (6.5) 20.4 (6.8)
SDAI 20.6 (6.3) 21.1 (6.6)
Tender Joint counts (68
joints)
12 (9) 13 (9)
Swollen joint counts (66
joints)
6 (5) 5 (4)
Erythrocyte Sedimenta-
tion Rate (mm/hr)
18 (14) 15 (13)
C-Reactive Protein (mg/
L)
8 (11) 7 (8)
Assessor Global Rating
(mm)
39 (18) 41 (18)
Patient Global Assess-
ment (mm)
43 (19) 46 (21)
Fatigue VAS (mm) 59 (25) 52 (25)
Pain VAS (mm) 40 (23) 43 (23)
Health Assessment
Questionnaire
1.2 (0.7) 1.2 (0.7)
EQ5D-5L 0.71 (0.16) 0.70 (0.19)
Larsen Score 11 (17) 9 (11)
Drug
Treatments
Oral Methotrexate 59 (35%) 67 (40%)
Subcut Methotrexate 22 (13%) 19 (11%)
Sulfasalazine 30 (18%) 19 (11%)
Leflunomide 12 (7%) 11 (7%)
Hydroxychloroquine 29 (17%) 37 (22%)
Azathioprine 1 (1%) 
Oral Methotrexate/
Hydroxychloroquine
7 (4%) 8 (5%)
Oral Methotrexate/
Sulfasalazine
2 (1%) 1 (1%)
Subcut
Methotrexate/
Hydroxychloroquine
3 (2%) 2 (1%)
Subcut
Methotrexate/
Sulfasalazine
2 (1%) 
Sulfasalazine/
Hydroxychloroquine
1 (1%) 3 (2%)
Showing mean (standard deviation) or number (%). Subcut=subcutaneous; ESR=
Erythrocyte Sedimentation Rate; CDAI= Clinical Disease Activity Index; SDAI= Simple
Disease Activity Index; VAS= Visual Analogue Scale; DAS28-CRP= Disease Activity
Score For 28 Joints Based On C-Reactive Protein; DAS28-ESR= Disease Activity Score
for 28 Joints based on ESR; EQ5D-5L= EuroQol 5 Dimension (5 levels).
Table 2
Additional Treatments During Trial Follow Up.
Intensive Management Standard Care
Additional drugs Oral MTX Subcut MTX SSZ LEF HCQ Oral MTX Subcut MTX SSZ LEF HCQ
n = 68 n = 27 n = 31 n = 12 n = 29 n = 76 n = 21 n = 22 n = 11 n = 37
None 13 (19%) 4 (15%) 3 (10%)  2 (7%) 20 (26%) 5 (24%) 7 (32%) 3 (27%) 
One DMARDs 23 (34%) 12 (44%) 12 (39%) 3 (25%) 5 (17%) 33 (43%) 12 (57%) 9 (41%) 5 (45%) 18 (49%)
Two DMARDs 13 (19%) 6 (22%) 11 (35%) 5 (33%) 9 (31%) 14 (18%) 1 (5%) 5 (23%)  11 (30%)
Etanercept 16 (24%) 4 (15%) 4 (13%) 4 (42%) 9 (31%) 4 (5%) 1 (5%) 1 (4%) 2 (18%) 4 (11%)
Benepali 1 (1%) 1 (4%) 1 (3%)  1 (4%) 2 (3%)    
Other TNF Inhibitor 2 (3%)    3 (10%) 3 (4%) 2 (10%)  1 (9%) 4 (11%)
Patient who had Azathioprine at baseline also had additional HCQ; SSZ= Sulfasalazine; HCQ= Hydroxychloroquine; MTX= methotrexate; LEF= Leflunomide;
DMARD=disease-modifying antirheumatic drugs.
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Economic analysis showed that the incremental cost-effectiveness
from a medical and personal social service cost was above current
willing to pay thresholds for medical cost in England. That said, our
analysis was based on the historic cost of biological treatment when
the trial was undertaken; biological acquisition costs have halved
since biosimilars were introduced making the current cost-effective-
ness of intensive management much more acceptable. The recent
move towards telephone and video consultations as a consequence
of the Coronavirus Pandemic will also decrease the costs of intensive
management. In addition, taking account of patients’ costs and the
loss of working time also makes intensive management far more
cost-effective.
In strategy trials like TITRATE, patients receive many interven-
tions, with uncertainty about which of them contribute most benefit.
Changing csDMARDs, starting biologics and providing psychosocial
care may all have contributed; we cannot know which was most
important. However, as a recent systematic review of different nurse
interventions showed no evidence they specifically reduced disease
activity compared to standard care [36], it is likely that patients bene-
fit most when intensive drug treatment is combined with psychoso-
cial care.
There has been debate about combining csDMARDs: some studies
and systematic reviews support their use [35, 37]; other studies and
guidelines question their value [38, 39]. The use of csDMARDs and
biologics in TITRATE cannot resolve this controversy but puts their
use into context. Furthermore, forty-five percent of assessed IM con-
sultations demonstrated low/poor fidelity to the taught psychosocial
care techniques. Another uncertainty is the frequency of patient
assessments. TITRATE aimed for monthly intensive management ses-
sions but less frequent sessions and/or incorporating email/skype
consulting methods [40] may have been sufficient  and more cost
effective. Our exploratory analysis of the impact of the number of
sessions of intensive management suggests infrequent assessments
appear suboptimal.
TITRATE had two main strengths. First, as a relatively large trial,
involving 39 centres, its findings are robust. Second, the predicted
and the actual outcomes were similar, showing it to have delivered
the expected clinical improvements [32]. TITRATE had several limita-
tions. Firstly, it did not compare the sustainability of remission
between groups [41, 42]: however, assessing standard care patients
more often than 6-monthly would mean they were no longer receiv-
ing standard care, invalidating them as controls. Secondly, TITRATE
only lasted 12 months: ideally strategy trials would last longer; 10-
year results have been reported for the BeSt strategy trial [43]. But
the organisational and funding complexities of long-term follow up
made this impractical in TITRATE. Thirdly, there is uncertainty about
which outcome is preferable: ACR-EULAR Boolean remissions appear
ideal but are rarely achieved; low DAS28-ESR has less benefit but
was achieved by almost half the intensive management patients.
Finally, intensive management is not always effective; TITRATE was
not designed to show how to manage non-responders. Failure to
respond to intensive treatment, particularly biologics, is common
and incurs high healthcare costs.
The intensity of RA drug treatment continues to increase, with
more combination csDMARDs and biologics used [10, 11]. This
increase resulted in 79% standard care TITRATE patients receiving
csDMARDs combinations or biologics; only 21% had DMARD mono-
therapy. The baseline csDMARDs used reflected English practice at
the time, with many patients starting sulphasalazine as an initial
csDMARD [44], and patients needed to receive two different
csDMARDs before starting biological treatments. By contrast the pre-
vious TICORA trial [32] showed that 88% standard care patients had
DMARD monotherapy. The increasing treatment intensity makes it
challenging to compare strategy trials completed years apart.
Table 4
Clinical Assessments At 12 Months In Intention To Treat Population. Estimated treatment effects are shown between trial arms.
Assessment Intensive Management Standard Care Linear Regression* Mixed Effect Models
N = 168 N = 167 Unadjusted P-value Adjusted P-value Unadjusted P-value Adjusted P-value
Mean (SE) Mean (SE) Coefficients Coefficient Coefficients Coefficient
(95% CI) (95% CI) (95% CI) (95% CI)
DAS28-ESR 3.4 (0.1) 3.8 (0.1) 0.6 (0.9, 0.3) <0.001 0.5 (0.8, 0.2) 0.001 0.4 (0.7, 0.2) 0.001 0.4 (0.6, 0.1) 0.003
Tender Joints 7.5 (0.7) 10.8 (0.8) 2.4 (4.4, 0.3) 0.023 2.7 (4.5, 0.8) 0.004 1.4 (3.4, 0.7) 0.187 1.7 (3.5, 0.2) 0.076
Swollen joints 3.5 (0.4) 4.9 (0.5) 1.9 (3.0, 0.7) 0.002 1.6 (2.7, 0.5) 0.004 1.5 (2.6, 0.5) 0.005 1.3 (2.3, 0.4) 0.006
ESR 17 (1) 15 (1) 1.5 (3.9, 1.0) 0.239 1.1 (3.4, 1.1) 0.329 1.1 (3.2, 1.0) 0.312 0.7 (2.7, 1.2) 0.463
CRP 9 (2) 7 (1) 0.9 (2.6, 4.4) 0.628 1.5 (1.8, 4.7) 0.372 0.6 (2.0, 3.1) 0.666 1.3 (0.9, 3.5) 0.239
Assessor Global 23 (2) 31 (2) 6 (12, 0.2) 0.043 8 (13, 3) 0.003 4 (9, 2) 0.169 5 (10, 1) 0.015
Patient Global 29 (2) 41 (2) 9 (15, 2) 0.010 11 (17, 6) <0.001 6 (12, 1) 0.026 9 (14, 4) <0.001
Fatigue 40 (2) 50 (2) 18 (24, 11) <0.001 15 (21, 9) <0.001 16 (21, 10) <0.001 13 (18, 8) <0.001
Pain 28 (2) 37 (2) 6.5 (13., 0.4) 0.064 8.4 (15, 2.3) 0.007 4 (11, 2) 0.161 6 (12, 1) 0.015
HAQ 1.0 (0.1) 1.1 (0.1) 0.1 (0.2, 0.0) 0.055 0.1 (0.2, 0.0) 0.046 0.1 (0.1, 0.0) 0.136 0.1 (0.2, 0.0) 0.137
EQ5D-5L 0.76 (0.02) 0.72 (0.02) 0.02 (0.02, 0.06) 0.248 0.03 (0.01, 0.07) 0.078 0.02 (0.01, 0.05) 0.275 0.02 (0.01, 0.05) 0.121
Larsen score 13 (1) 10 (1) 0.5 (0.1, 1.0) 0.095 0.4 (0.2, 0.9) 0.175    
* Change from baseline analysed and adjustments made for demographics (age, gender, ethnicity, disease duration) design factors (NHS region) and baseline score; standard of
care arm was the reference group; SE =standard errors; CI= 95% confidence Intervals.
Table 3
Remission rates with Intensive Management in Intention to Treat Population. The groups were compared using unadjusted and adjusted odds
ratios.
Remission Classification Intensive Management Standard Care Unadjusted Adjusted*
Proportion (95% CI) Proportion (95% CI) OR (95% CI) P-value OR (95% CI) P-value
DAS28-ESR 32% (25%, 40%) 18% (12%, 24%) 2.17 (1.28, 3.68) 0.004 2.38 (1.36,4.17) 0.002
DAS28-CRP 21% (15%, 27%) 10% (5%, 15%) 2.44 (1.27, 4.70) 0.008 2.52 (1.28,4.99) 0.008
SDAI 17% (11%, 23%) 10% (6%, 15%) 1.81 (0.94, 3.47) 0.074 1.90 (0.97,3.72) 0.060
CDAI 18% (12%, 24%) 10% (6%, 15%) 1.92 (1.00, 3.68) 0.049 2.10 (1.07,4.09) 0.030
ACR/EULAR Boolean 13% (8%, 18%) 6% (2%, 10%) 2.32 (1.04, 5.18) 0.040 2.44 (1.06,5.64) 0.036
* Adjusted for demographics (age, gender, ethnicity, disease duration), design factors (NHS region) and baseline values; ACR/EULAR Boolean
remissions were only adjusted for demographics; standard of care armwas the reference group; OR = odds ratio; CI = confidence intervals.
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However, unlike the recent negative results from other trials [14]
implementing a treat-to-target approach, by combining health care
professionals before they delivered intensive management and by
providing psychosocial support together with increasing drug treat-
ment, we found intensive management approaches increase remis-
sions in the modern era.
The findings in TITRATE highlight several uncertainties. Firstly,
identifying why many patients do not respond to intensive manage-
ment; analysis of baseline assessments in TITRATE and similar trials
may help identify potential non-responders. Secondly, there is lim-
ited information about the optimal duration of intensive manage-
ment strategies in patients who have responded but not achieved
sustained remissions. Long-term follow-up of a previous intensive
treatment trial suggests benefits decline over time [45], implying per-
sisting intensive management may be needed. Thirdly, simple blood
tests like the ESR did not help monitor responses in TITRATE. This
finding is in keeping with previous research by Kay and colleagues,
who reported that ESR levels often failed to correlate with disease
activity measured by joint counts and global assessments in a large
observational study [46]; alternative strategies, potentially using
multiple measures, may be preferable [47].
We conclude intensive management using treat-to-target
approaches benefits patients with moderate established RA as well as
patients with active early disease who have been extensively studied
in previous trials. TITRATE therefore supports extending treat-to-tar-
get approaches to most RA patients who are not yet in remission or
low disease activity states. It also highlights the growing importance
of non-pharmacological interventions such as psycho-social support.
Although our economic analysis showed intensive management
exceeded the cost-effective threshold ranges currently used by UK
decision makers (£30,000/quality-adjusted life-year gained), this
estimate reflected historic biological prices at the time of the trial.
Adopting current drug acquisition costs would increase the probabil-
ity intensive management is cost-effective; estimating the impact of
remissions after the trial ended would also increase apparent cost-
effectiveness.
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Table 5
Adverse Events In TITRATE Trial.
Category Body System Intensive Management Standard Care
Deaths Cardiovascular Ruptured thoracic aneurysm 
Neoplasia Metastatic cancer 
Respiratory  Pulmonary fibrosis
Other Individual Serious Adverse Events Allergy  Angioedema
Cardiovascular Heart failure Microvascular angina
Myocardial Infarction Paroxysmal arrhythmia
Dyspnoea/chest tightness 
Hypotension headache 
Gastrointestinal Small bowel obstruction Diverticular disease
 Diverticulitis
 Gallstones
Neoplasia  Breast cancer
Immunological Tonsillitis with neutropenia 
Musculoskeletal RA flare/shoulder capsulitis 
Neurological Stroke Sepsis
Other Pregnant Dizziness/syncope
Collapsed unknown cause 
Cerebral spinal fluid leak 
Respiratory Chest infection/Asthma Exacerbation of Asthma
All Other Adverse Events Number 114 Episodes 151 Episodes
Allergies 1 (1%) 3 (2%)
Dermatological 8 (7%) 17 (11%)
Cardiovascular 5 (4%) 8 (5%)
Eyes, Ear, Nose & Throat 10 (9%) 15 (10%)
Gastro-Intestinal 9 (8%) 27 (18%)
Genitourinary/Renal 3 (3%) 10 (7%)
Haematological 5 (4%) 3 (2%)
Hepatic 6 (5%) 2 (1%)
Immunological 2 (2%) 1 (1%)
Musculoskeletal 21 (18%) 17 (11%)
Neoplasia 1 (1%) 3 (2%)
Neurological 11 (10%) 6 (4%)
Other 10 (9%) 8 (5%)
Psychological 0 (0%) 2 (1%)
Respiratory 22 (19%) 29 (19%)
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